CGRP: A Dual Role in the Immune System – Contextual Functions in Inflammation, Resolution, and Cancer

Overview

Calcitonin gene-related peptide (CGRP) serves as a dual mediator in immune responses, exhibiting both anti-inflammatory and pro-inflammatory effects depending on the context. This review discusses CGRP's roles in various immune processes, including inflammation, autoimmunity, and cancer.

Background

CGRP is traditionally known for its role in nociception and vasodilation, but recent findings reveal its significant involvement in immune modulation. Understanding CGRP's context-dependent functions is crucial for developing targeted therapies for inflammatory and autoimmune diseases, as well as cancer.

Data Highlights

No numerical or trial data presented in the article.

Key Findings

• CGRP exerts anti-inflammatory effects on various immune cells, including macrophages and neutrophils.
• In chronic conditions, CGRP can promote CD8+ T cell exhaustion and suppress Th1 responses.
• During acute viral infections, CGRP paradoxically enhances Th1 differentiation.
• Aberrant CGRP signaling is implicated in exacerbating conditions like psoriasis and autoimmune encephalomyelitis.
• In the tumor microenvironment, CGRP can suppress anti-tumor immunity and stimulate cancer cell growth.

Clinical Implications

The dual role of CGRP in immune modulation suggests that therapies targeting CGRP may need to be context-aware.

Conclusion

CGRP's multifaceted roles in the immune system present both challenges and opportunities for therapeutic interventions.

Related Resources & Content

1. American Headache Society, PubMed, 2024 -- Calcitonin gene-targeting therapies are a first-line option for the prevention of migraine
2. American Headache Society, Headache: The Journal of Head and Face Pain, 2024 -- Calcitonin gene-targeting therapies are a first-line option for the prevention of migraine
3. Atogepant for preventing migraine, National Institutes of Health, 2024 -- Atogepant for preventing migraine
4. BMJ, 2025 -- New treatments for migraine: CGRP monoclonal antibodies, gepants, and ditans
5. Frontiers in Immunology — CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease
6. Frontiers in Immunology — Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease
7. Expression of Gastrin-Releasing Peptide and Its Receptor in Tumor-Associated Macrophages of Clear Cell Renal Cell Carcinoma: Implications for Immune Cell Modulation
8. Frontiers in Immunology — CURE: a phase-based therapeutic framework for chronic inflammation
9. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update - PubMed
10. Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update - Charles - 2024 - Headache: The Journal of Head and Face Pain - Wiley Online Library
11. Atogepant for preventing migraine
12. New treatments for migraine: CGRP monoclonal antibodies, gepants, and ditans
13. Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Chronic Migraine with Medication Overuse: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (P12-12.008) | Neurology
14. Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence - PMC
15. AIMOVIG (erenumab-aooe) injection, for subcutaneous use
16. Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment - PMC
17. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review - PMC
18. Frontiers | SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials
19. Sensory nerve release of CGRP increases tumor growth in HNSCC by suppressing TILs - PubMed